The ACP1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted population derived from the HeLa human cell line, designed to eliminate functional ACP1 expression. This polyclonal knockout reagent offers a genetically heterogeneous pool of cells, enabling loss-of-function analyses in a cancer-relevant epithelial background. ACP1 encodes a low-molecular-weight protein tyrosine phosphatase that negatively regulates multiple signaling cascades. By disrupting ACP1, researchers can monitor enhanced and prolonged tyrosine phosphorylation across critical pathways. The cells are provided as a ready-to-use tool for functional genomics, drug target validation, and phosphatase-dependent signaling studies.
HeLa cells, originally isolated from a human cervical adenocarcinoma, are a widely employed tumorigenic epithelial model. This HPV18-positive line maintains active growth factor signaling and is extensively characterized in cancer research. The robust and reproducible nature of HeLa cells offers a consistent platform for examining ACP1-mediated processes. Its epithelial origin and transformed phenotype make it particularly relevant for investigating cervical and other solid tumor signaling networks.
ACP1 functions as a phosphotyrosine phosphatase that directly dephosphorylates activated receptor tyrosine kinases and downstream effectors. In ephrin receptor signaling, ACP1 targets EphB1 and modulates STAT5 activation, influencing cell adhesion and migration. Within insulin and PDGF cascades, it acts on insulin receptor substrate and PDGFR, regulating metabolic and mitogenic responses. ACP1 also interfaces with T cell receptor components such as ZAP-70 in immune contexts, though its role in HeLa cells centers on epithelial oncogenic pathways. Key interacting partners include EphB1, EGFR, PDGFR, and the adaptor Grb2, positioning ACP1 at a convergence point of multiple signaling circuits.
Disruption of ACP1 in HeLa cells is particularly informative because these cells retain active Ephrin, insulin, and PDGF pathways that are dysregulated in cervical and other cancers. ACP1??s involvement in cervical cancer pathogenesis and type 2 diabetes??partly through insulin receptor substrate dephosphorylation??underscores the model??s relevance. Loss of ACP1 may potentiate receptor tyrosine kinase signaling, enabling dissection of phosphatase deficiency effects on proliferation, survival, and drug sensitivity. Additionally, the HPV18-positive background permits exploration of viral?Chost phosphatase interactions that may drive transformation.
Researchers can employ these knockout cells in phosphatase activity assays to confirm enzyme loss, western blotting for phosphotyrosine profiling, and immunofluorescence microscopy to track signaling compartmentalization. Migration and drug sensitivity assays facilitate assessment of ACP1??s roles in motility and chemoresistance. Typical applications include cancer signaling studies, phosphatase inhibitor testing, and mechanistic investigation of tyrosine phosphorylation networks. These cells also serve as comparators in CRISPR screens or inducible expression experiments. For further technical details or to discuss custom solutions, please contact Ascent Research.
